Literature DB >> 29635121

N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.

Luigino Calzetta1, Paola Rogliani2, Francesco Facciolo3, Barbara Rinaldi4, Mario Cazzola5, Maria Gabriella Matera6.   

Abstract

AIMS: N-Acetylcysteine (NAC) reduces the risk of exacerbation of chronic obstructive pulmonary disease (COPD). Although NAC also has anti-inflammatory activity, the detailed mechanism leading to its protective role remains to be elucidated. We tested the impact of NAC against the effects of lipopolysaccharide (LPS) in an ex vivo model of COPD exacerbation, and investigated the role of neurokinin A (NKA) in this context. MAIN
METHODS: Isolated airways from COPD patients were incubated overnight with LPS (100 ng/ml). NAC was tested at concentrations resembling the plasma levels elicited by oral administration of NAC at 200 mg/day (very low dose), 600 mg/day (low dose) and 1.200 mg/day (high dose). KEY
FINDINGS: NAC at high concentrations normalized the peroxidase activity, H2O2, malondialdehyde (MDA), nitric oxide, glutathione (GSH), total antioxidant capacity (TAC), and interleukin 6 (IL-6) (overall change 34.32% ± 4.22%, P < 0.05 vs. LPS-treated). NAC at low concentrations modulated peroxidase activity, H2O2, MDA, GSH, TAC, and IL-6 (overall change 34.88% ± 7.39%, P < 0.05 vs. LPS-treated). NAC at very-low concentrations was effective on peroxidase activity, H2O2, GSH, and IL-6 (overall change 35.05 ± 7.71%, P < 0.05 vs. LPS-treated). Binary logistic regression analysis indicated that the modulatory effect of NAC on NKA levels was associated with a reduction of pro-oxidant factors and IL-6, and selectively blocking the NK2 receptor abolished such an association. SIGNIFICANCE: This study demonstrates that, along with its well-known antioxidant activity, the protective effect of NAC against the detrimental effect of LPS is due to the modulation of NKA and IL-6 levels.
Copyright © 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory effect; Anti-oxidant effect; COPD exacerbation; Lipopolysaccharide; N-Acetylcysteine

Mesh:

Substances:

Year:  2018        PMID: 29635121     DOI: 10.1016/j.biopha.2018.04.011

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

Review 1.  Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models.

Authors:  Luigino Calzetta; Elena Pistocchini; Beatrice Ludovica Ritondo; Francesco Cavalli; Francesca Camardelli; Paola Rogliani
Journal:  Heliyon       Date:  2022-06-22

Review 2.  Use of Thiols in the Treatment of COVID-19: Current Evidence.

Authors:  Mario Cazzola; Paola Rogliani; Sundeep Santosh Salvi; Josuel Ora; Maria Gabriella Matera
Journal:  Lung       Date:  2021-08-27       Impact factor: 2.584

Review 3.  N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review.

Authors:  Marta Guerini; Giorgia Condrò; Valeria Friuli; Lauretta Maggi; Paola Perugini
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-11

4.  N-Acetyl Cysteine Modulates the Inflammatory and Oxidative Stress Responses of Rescued Growth-Arrested Dental Pulp Microtissues Exposed to TEGDMA in ECM.

Authors:  Gili Kaufman; Drago Skrtic
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

5.  The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.

Authors:  Javed Akhter; Grégory Quéromès; Krishna Pillai; Vahan Kepenekian; Samina Badar; Ahmed H Mekkawy; Emilie Frobert; Sarah J Valle; David L Morris
Journal:  Viruses       Date:  2021-03-06       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.